KUBESPHERE
27.5.2021 09:50:06 CEST | Business Wire | Press release
KubeSphere Community announced the general availability of KubeSphere v3.1.0. KubeSphere, as an app-centric distributed operating system running on top of Kubernetes, has further expanded its portfolio to deliver more robust experiences for users across the globe, enabling DevOps teams to run Kubernetes workloads where and when they want with ease and security.
“KubeSphere has emerged as one of the most popular Kubernetes platforms ,” said Ray Zhou, Head of the KubeSphere project. “The release of KubeSphere 3.1 marks an important milestone as we further empower enterprises to gain first-mover advantages especially in edge computing.”
Taking Kubernetes From Hybrid Multi-Cloud to Edge
KubeSphere v3.1.0 provides an enabling environment for users as they can deploy production workloads not just across clouds but also at the edge . Besides, the new Metering and Billing function helps IT administrators better understand infrastructure operating costs. Existing features of multi-cluster management , multi-tenant management, observability, DevOps, application lifecycle management , and microservices governance have also been enhanced to ensure better user experiences across clusters and clouds .
Major updates include:
- Metering and billing to track infrastructure cost
- Edge node management for orchestrating apps and edge devices
- Lightweight Kubernetes multi-cloud and multi-cluster management
- Unified Kubernetes monitoring in one dashboard
- Easier Kubernetes installation
- Enhanced security with authentication and multi-tenancy
A full list of new features can be found in Release Note 3.1.0 . For a detailed introduction and interpretation, check out the latest KubeSphere 3.1.0 announcement
Commitment to Open-Source and Community
KubeSphere is making great strides on its international journey with over 100,000 downloads across 90 countries and regions to date. The KubeSphere console currently supports four official languages - English, Simplified Chinese, Traditional Chinese and Spanish.
“When you take a step back and reflect on how far KubeSphere has come, it is not surprising to find that it has become one of the most widely used container platforms not just in our country, but also around the world,” Ray added. “Our contributors from all corners of the world have shown us what open source is all about. And this is exactly what has been driving us to push the limits of what’s possible with Kubernetes.”
KubeSphere v3.1.0 remains committed to fully open source with an ever-expanding ecosystem, also helps developers to deploy code with several clicks on the friendly console, and brings integrated observability and powerful Kubernetes DevOps strategies for the Ops team.
About KubeSphere
KubeSphere is an open-source container platform based on Kubernetes. It provides full-stack IT automated operation and streamlined DevOps workflows. KubeSphere offers wizard web UI and enterprise-grade features for operation and maintenance, including multi-cloud and multi-cluster management , DevOps (CI/CD ), application lifecycle management , service mesh , multi-tenant , observability ,storage and network , and GPU support .
For more information, visit website https://kubesphere.io , GitHub https://github.com/kubesphere/kubesphere and follow @KubeSphere on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005328/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom